<html><head><link rel="stylesheet" type="text/css" href="css/style.css"></head><body><div id="main"><h1>Scignal</h1></div> <div class="container"><div class="row"><div class="search"><h2>All Results for : "chimeric antigen receptor" OR "CAR T" OR "CAR-"</a></h2></div><table><tr><td class="head"><h3>BioRxiv</h3></td><td class="head"><h3>PubMed</h3></td></tr><tr><div class="row"><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Impaired tumor death receptor signaling drives resistance to CAR T cell therapy</h4><p><a href="https://www.biorxiv.org/content/10.1101/627562v1">Link</a></p><p><b>Date:</b> 2019-05-05</p><p><b>Authors:</b> Nathan Singh ... Marco Ruella</p><p><b>Downloads:</b> 1273</p><p><b>Relevance Score:</b> 0.57</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Cellular immunotherapy using T cells engineered to express chimeric antigen receptors targeting CD19 (CART19) leads to long-term remission in patients with B-cell malignancies.  Unfortunately, a significant fraction of patients demonstrate primary resistance to CART19 or experience relapse after achieving remission.</p></div></td></div><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Engineering light-controllable CAR T cells for cancer immunotherapy.</h4><p><a href="https://ncbi.nlm.nih.gov/pubmed/32128416">Link</a></p><p><b>Date:</b> 03/04/2020</p><p><b>Authors:</b> Ziliang Huang ...  Yingxiao Wang</p><p><b>Journal:</b> Sci Adv</p><p><b>IF (7 or above):</b> 12.53</p><p><b>Relevance Score:</b> 0.57</p></div><div class="everything-else-tail"><p><b>Abstract:</b> T cells engineered to express chimeric antigen receptors (CARs) can recognize and engage with target cancer cells with redirected specificity for cancer immunotherapy.  However, there is a lack of ideal CARs for solid tumor antigens, which may lead to severe adverse effects.</p></div></td></div></tr><tr><div class="row"><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Functional effects of chimeric antigen receptor co-receptor signaling domains in human Tregs</h4><p><a href="https://www.biorxiv.org/content/10.1101/749721v1">Link</a></p><p><b>Date:</b> 2019-08-29</p><p><b>Authors:</b> Nicholas A.J. Dawson ... Megan K Levings</p><p><b>Downloads:</b> 781</p><p><b>Relevance Score:</b> 0.57</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Antigen-specific regulatory T cells (Tregs) engineered with chimeric antigen receptor (CARs) are a potent immunosuppressive cellular therapy in multiple disease models.  To date the majority of CAR Treg studies employed second generation CARs, encoding a CD28 or 4-1BB co-receptor signaling domain and CD3zeta, but it was not known if this CAR design was optimal for Tregs.</p></div></td></div><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Enhanced efficacy and limited systemic cytokine exposure with membrane-anchored interleukin-12 T-cell therapy in murine tumor models.</h4><p><a href="https://ncbi.nlm.nih.gov/pubmed/31959727">Link</a></p><p><b>Date:</b> 01/21/2020</p><p><b>Authors:</b> Ling Zhang ...  Christian S Hinrichs</p><p><b>Journal:</b> J Immunother Cancer</p><p><b>IF (7 or above):</b> 8.66</p><p><b>Relevance Score:</b> 0.29</p></div><div class="everything-else-tail"><p><b>Abstract:</b> BACKGROUND: Interleukin-12 (IL-12) is a potent, proinflammatory cytokine that holds promise for cancer immunotherapy, but its clinical use has been limited by its toxicity.  To minimize systemic exposure and potential toxicity while maintaining the beneficial effects of IL-12, we developed a novel I ....</p></div></td></div></tr><tr><div class="row"><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: convertibleCARs: A chimeric antigen receptor system for flexible control of activity and antigen targeting</h4><p><a href="https://www.biorxiv.org/content/10.1101/696401v2">Link</a></p><p><b>Date:</b> 2019-07-09</p><p><b>Authors:</b> Kyle E. Landgraf ... Kaman Chan Kim</p><p><b>Downloads:</b> 723</p><p><b>Relevance Score:</b> 0.57</p></div><div class="everything-else-tail"><p><b>Abstract:</b> We have developed a chimeric antigen receptor (CAR) platform that functions as a modular system to address limitations of current CAR therapies.  An inert form of the NKG2D extracellular domain (iNKG2D) was used as the ectodomain of the CAR to generate convertibleCAR-T cells.</p></div></td></div><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Novel, genetically induced mouse model that recapitulates the histological morphology and immunosuppressive tumor microenvironment of metastatic peritoneal carcinomatosis.</h4><p><a href="https://ncbi.nlm.nih.gov/pubmed/32111730">Link</a></p><p><b>Date:</b> 02/29/2020</p><p><b>Authors:</b> Ssu-Hsueh Tseng ...  Chien-Fu Hung</p><p><b>Journal:</b> J Immunother Cancer</p><p><b>IF (7 or above):</b> 8.66</p><p><b>Relevance Score:</b> 0.14</p></div><div class="everything-else-tail"><p><b>Abstract:</b> BACKGROUND: Peritoneal carcinomatosis is a hallmark of advanced peritoneal tumor progression, particularly for tubal/ovarian high-grade serous carcinomas (HGSCs).  Patients with peritoneal carcinomatosis have poor survival rates and are difficult to treat clinically due to widespread tumor dissemina ....</p></div></td></div></tr><tr><div class="row"><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Overcoming Immunological Resistance Enhances the Efficacy of a Novel anti-tMUC1 CAR T Cell Treatment Against Pancreatic Ductal Adenocarcinoma</h4><p><a href="https://www.biorxiv.org/content/10.1101/642934v1">Link</a></p><p><b>Date:</b> 2019-05-20</p><p><b>Authors:</b> Mahboubeh Yazdanifar ... Pinku Mukherjee</p><p><b>Downloads:</b> 316</p><p><b>Relevance Score:</b> 0.57</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Chimeric antigen receptor engineered T cells (CAR T cells) have shown remarkable success in treating hematologic cancers.  However, this efficacy has yet to translate to treatment in solid tumors.</p></div></td></div><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: CCL5-armed oncolytic virus augments CCR5-engineered NK cell infiltration and antitumor efficiency.</h4><p><a href="https://ncbi.nlm.nih.gov/pubmed/32098828">Link</a></p><p><b>Date:</b> 02/26/2020</p><p><b>Authors:</b> Feng Li ...  Yi Zhang</p><p><b>Journal:</b> J Immunother Cancer</p><p><b>IF (7 or above):</b> 8.66</p><p><b>Relevance Score:</b> 0.14</p></div><div class="everything-else-tail"><p><b>Abstract:</b> BACKGROUND: Natural killer (NK) cells have potent antitumor activities.  Nevertheless, adoptive transfer therapy of NK cells has gained very limited success in patients with solid tumors as most infused NK cells remain circulating in the peripheral blood instead of entering tumor sites.</p></div></td></div></tr><tr><div class="row"><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Chlorotoxin Redirects Chimeric Antigen Receptor T Cells for Specific and Effective Targeting of Glioblastoma</h4><p><a href="https://www.biorxiv.org/content/10.1101/2020.01.24.918888v1">Link</a></p><p><b>Date:</b> 2020-01-25</p><p><b>Authors:</b> Dongrui Wang ... Christine E. Brown</p><p><b>Downloads:</b> 194</p><p><b>Relevance Score:</b> 0.57</p></div><div class="everything-else-tail"><p><b>Abstract:</b> While chimeric antigen receptor (CAR) T cells have demonstrated antitumor activity against glioblastoma (GBM), tumor heterogeneity remains a critical challenge.  To more effectively target heterogeneous GBMs, we report the development of a novel peptide-based CAR exploiting the GBM-binding potential of chlorotoxin (CLTX).</p></div></td></div><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: T-cell lymphoma secondary to checkpoint inhibitor therapy.</h4><p><a href="https://ncbi.nlm.nih.gov/pubmed/32114498">Link</a></p><p><b>Date:</b> 03/02/2020</p><p><b>Authors:</b> Kartik Anand ...  Swaminathan Iyer</p><p><b>Journal:</b> J Immunother Cancer</p><p><b>IF (7 or above):</b> 8.66</p><p><b>Relevance Score:</b> 0.14</p></div><div class="everything-else-tail"><p><b>Abstract:</b> BACKGROUND: Murine model suggests programmed cell death-1 (PD-1), an immune checkpoint not only plays role in tumor escape but is also a tumor suppressor for T-cells.  But until, no reports of secondary T-cell lymphoma postuse of immune checkpoint inhibitors (ICIs) has been reported.</p></div></td></div></tr><tr><div class="row"><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Tumor control via targeting PD-L1 with chimeric antigen receptor modified NK cells</h4><p><a href="https://www.biorxiv.org/content/10.1101/2020.01.30.926535v1">Link</a></p><p><b>Date:</b> 2020-01-30</p><p><b>Authors:</b> Yvette Robbins ... Clint T. Allen</p><p><b>Downloads:</b> 165</p><p><b>Relevance Score:</b> 0.57</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Failed T cell-based immunotherapies in the presence of genomic alterations in antigen presentations pathways may be overcome by NK cell-based immunotherapy.  This approach may still be limited by the presence of immunosuppressive myeloid populations.</p></div></td></div><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Defining current gaps in quality measures for cancer immunotherapy: consensus report from the Society for Immunotherapy of Cancer (SITC) 2019 Quality Summit.</h4><p><a href="https://ncbi.nlm.nih.gov/pubmed/31949040">Link</a></p><p><b>Date:</b> 01/17/2020</p><p><b>Authors:</b> Sara Pai ...  Howard L Kaufman</p><p><b>Journal:</b> J Immunother Cancer</p><p><b>IF (7 or above):</b> 8.66</p><p><b>Relevance Score:</b> 0.14</p></div><div class="everything-else-tail"><p><b>Abstract:</b> BACKGROUND: Quality measures are important because they can help improve and standardize the delivery of cancer care among healthcare providers and across tumor types.  In an environment characterized by a rapidly shifting immunotherapeutic landscape and lack of associated long-term outcome data, de ....</p></div></td></div></tr><tr><div class="row"><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Perfect adaptation of CD8+ T cell responses to constant antigen input over a wide range of affinity is overcome by costimulation</h4><p><a href="https://www.biorxiv.org/content/10.1101/535385v2">Link</a></p><p><b>Date:</b> 2019-01-30</p><p><b>Authors:</b> Nicola Trendel ... Omer Dushek</p><p><b>Downloads:</b> 687</p><p><b>Relevance Score:</b> 0.29</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Maintaining and limiting T cell responses to constant antigen stimulation is critical to control pathogens and maintain self-tolerance, respectively.  Antigen recognition by T cell receptors (TCRs) induces signalling that activates T cells to produce cytokines and also leads to the downregulation of surface TCRs.</p></div></td></div><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Oncolytic adenovirus shapes the ovarian tumor microenvironment for potent tumor-infiltrating lymphocyte tumor reactivity.</h4><p><a href="https://ncbi.nlm.nih.gov/pubmed/31940588">Link</a></p><p><b>Date:</b> 01/15/2020</p><p><b>Authors:</b> João Manuel Santos ...  Akseli Hemminki</p><p><b>Journal:</b> J Immunother Cancer</p><p><b>IF (7 or above):</b> 8.66</p><p><b>Relevance Score:</b> 0.14</p></div><div class="everything-else-tail"><p><b>Abstract:</b> BACKGROUND: Ovarian cancers often contain significant numbers of tumor-infiltrating lymphocytes (TILs) that can be readily harnessed for adoptive T-cell therapy (ACT).  However, the immunosuppressive ovarian tumor microenvironment and lack of tumor reactivity in TILs can limit the effectiveness of t ....</p></div></td></div></tr><tr><div class="row"><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Functionalized microcarriers improve T cell manufacturing by facilitating migratory memory T cell production and increasing CD4/CD8 ratio</h4><p><a href="https://www.biorxiv.org/content/10.1101/646760v1">Link</a></p><p><b>Date:</b> 2019-05-23</p><p><b>Authors:</b> Nathan J. Dwarshuis ... Krishnendu Roy</p><p><b>Downloads:</b> 622</p><p><b>Relevance Score:</b> 0.29</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Adoptive cell therapies (ACT) using chimeric antigen receptor (CAR) T cells have shown promise in treating cancer, but manufacturing large numbers of high quality cells remains challenging.  Critically, current T cell expansion technologies only partially recapitulate the in vivo microenvironment found in the human lymph nodes.</p></div></td></div><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Increased antitumor efficacy of PD-1-deficient melanoma-specific human lymphocytes.</h4><p><a href="https://ncbi.nlm.nih.gov/pubmed/32001504">Link</a></p><p><b>Date:</b> 01/31/2020</p><p><b>Authors:</b> Lucine Marotte ...  Nathalie Labarriere</p><p><b>Journal:</b> J Immunother Cancer</p><p><b>IF (7 or above):</b> 8.66</p><p><b>Relevance Score:</b> 0.14</p></div><div class="everything-else-tail"><p><b>Abstract:</b> BACKGROUND: Genome editing offers unique perspectives for optimizing the functional properties of T cells for adoptive cell transfer purposes.  So far, 
METHODS: Here we used the transfection of CAS9/sgRNA ribonucleoproteic complexes to edit 
RESULTS: Here we demonstrated the feasibility to edit 
CO ....</p></div></td></div></tr><tr><div class="row"><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Identification of human CD4+ T cell populations with distinct antitumor activity</h4><p><a href="https://www.biorxiv.org/content/10.1101/2019.12.31.891317v1">Link</a></p><p><b>Date:</b> 2020-01-02</p><p><b>Authors:</b> Michelle H. Nelson ... Chrystal Paulos</p><p><b>Downloads:</b> 418</p><p><b>Relevance Score:</b> 0.29</p></div><div class="everything-else-tail"><p><b>Abstract:</b> How naturally arising human CD4+ T helper subsets impact tumor immunity is unknown.  We reported that human CD4+CD26high T cells elicit potent immunity against solid tumor malignancies.</p></div></td></div><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Regulatory T-cell depletion in the setting of autologous stem cell transplantation for multiple myeloma: pilot study.</h4><p><a href="https://ncbi.nlm.nih.gov/pubmed/31940591">Link</a></p><p><b>Date:</b> 01/15/2020</p><p><b>Authors:</b> Benjamin A Derman ...  Justin Kline</p><p><b>Journal:</b> J Immunother Cancer</p><p><b>IF (7 or above):</b> 8.66</p><p><b>Relevance Score:</b> 0.14</p></div><div class="everything-else-tail"><p><b>Abstract:</b> BACKGROUND: Progression after high-dose melphalan with autologous stem cell transplantation (ASCT) in multiple myeloma (MM) may be due in part to immune dysfunction.  Regulatory T (Treg) cells reconstitute rapidly after ASCT and inhibit immune responses against myeloma cells.</p></div></td></div></tr><tr><div class="row"><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Three-Compartment Model of CAR T-cell Immunotherapy</h4><p><a href="https://www.biorxiv.org/content/10.1101/779793v1">Link</a></p><p><b>Date:</b> 2019-09-24</p><p><b>Authors:</b> Brendon de Jesus Rodrigues ... Regina C. Almeida</p><p><b>Downloads:</b> 353</p><p><b>Relevance Score:</b> 0.29</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Immunotherapy has gained great momentum with CAR T (chimeric antigen receptor) cellular therapy, in which the patients T lymphocytes are genetically manipulated to recognize tumor-specific antigens to increase elimination efficiency.  Although recently approved by FDA to treat B cell malignancies, issues such as dose, administration protocol, toxicity, resistance to immunotherapy, among others, remain open and are the subject of intense research nowadays.</p></div></td></div><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Sixth Immunotherapy of Cancer conference (ITOC): advances and perspectives-a meeting report.</h4><p><a href="https://ncbi.nlm.nih.gov/pubmed/32114499">Link</a></p><p><b>Date:</b> 03/02/2020</p><p><b>Authors:</b> Catarina Pinto ...  Sebastian Kobold</p><p><b>Journal:</b> J Immunother Cancer</p><p><b>IF (7 or above):</b> 8.66</p><p><b>Relevance Score:</b> 0.14</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Immunotherapy has moved to the forefront of cancer treatment, illustrated by the accelerating pace of novel therapy approvals.  In this complex environment, scientists rely on cutting edge conferences to stay informed.</p></div></td></div></tr><tr><div class="row"><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Feasibility of real-time in vivo 89Zr-DFO-labeled CAR T-cell trafficking using PET imaging</h4><p><a href="https://www.biorxiv.org/content/10.1101/789727v1">Link</a></p><p><b>Date:</b> 2019-10-01</p><p><b>Authors:</b> Suk Hyun Lee ... Jin-Sook Ryu</p><p><b>Downloads:</b> 110</p><p><b>Relevance Score:</b> 0.29</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Introduction: Chimeric antigen receptor (CAR) T-cells have been developed recently, producing impressive outcomes in patients with hematologic malignancies.  However, there is no standardized method for cell trafficking and in vivo CAR T-cell monitoring.</p></div></td></div><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: T lymphocyte-targeted immune checkpoint modulation in glioma.</h4><p><a href="https://ncbi.nlm.nih.gov/pubmed/32051289">Link</a></p><p><b>Date:</b> 02/13/2020</p><p><b>Authors:</b> William James Kelly ...  Mark Gilbert</p><p><b>Journal:</b> J Immunother Cancer</p><p><b>IF (7 or above):</b> 8.66</p><p><b>Relevance Score:</b> 0.14</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Immunomodulatory therapies targeting inhibitory checkpoint molecules have revolutionized the treatment of solid tumor malignancies.  Concerns about whether systemic administration of an immune checkpoint inhibitor could impact primary brain tumors were answered with the observation of definitive res ....</p></div></td></div></tr><tr><div class="row"><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Post-translational covalent assembly of CAR and synNotch receptors for programmable antigen targeting</h4><p><a href="https://www.biorxiv.org/content/10.1101/2020.01.17.909895v1">Link</a></p><p><b>Date:</b> 2020-01-17</p><p><b>Authors:</b> Jason Lohmueller ... Olivera J. Finn</p><p><b>Downloads:</b> 322</p><p><b>Relevance Score:</b> 0.14</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Chimeric antigen receptors (CARs) and synthetic Notch (synNotch) receptors are engineered cell-surface receptors that sense a target antigen and respond by activating T cell receptor signaling or a customized gene program, respectively.  To expand the targeting capabilities of these receptors, we have developed switchable adaptor receptor systems for which receptor specificity can be directed post-translationally via covalent attachment of a co-administered antibody.</p></div></td></div><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Escherichia coli adhesion portion FimH functions as an adjuvant for cancer immunotherapy.</h4><p><a href="https://ncbi.nlm.nih.gov/pubmed/32132528">Link</a></p><p><b>Date:</b> 03/06/2020</p><p><b>Authors:</b> Wei Zhang ...  Jun-O Jin</p><p><b>Journal:</b> Nat Commun</p><p><b>IF (7 or above):</b> 11.80</p><p><b>Relevance Score:</b> 0.14</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Induction of antigen-specific immune activation by the maturation of dendritic cells (DCs) is a strategy used for cancer immunotherapy.  In this study, we find that FimH, which is an Escherichia coli adhesion portion, induces toll-like receptor 4-dependent and myeloid differentiation protein 2-indep ....</p></div></td></div></tr><tr><div class="row"><td></td><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Juvenile cleaner fish can socially learn the consequences of cheating.</h4><p><a href="https://ncbi.nlm.nih.gov/pubmed/32127522">Link</a></p><p><b>Date:</b> 03/04/2020</p><p><b>Authors:</b> Noa Truskanov ...  Redouan Bshary</p><p><b>Journal:</b> Nat Commun</p><p><b>IF (7 or above):</b> 11.80</p><p><b>Relevance Score:</b> 0.14</p></div><div class="everything-else-tail"><p><b>Abstract:</b> Social learning is often proposed as an important driver of the evolution of human cooperation.  In this view, cooperation in other species might be restricted because it mostly relies on individually learned or innate behaviours.</p></div></td></div></tr><tr><div class="row"><td></td><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Noncoding RNAs in cancer immunity: functions, regulatory mechanisms, and clinical application.</h4><p><a href="https://ncbi.nlm.nih.gov/pubmed/32122338">Link</a></p><p><b>Date:</b> 03/03/2020</p><p><b>Authors:</b> Le Zhang ...  Xiulan Su</p><p><b>Journal:</b> Mol. Cancer</p><p><b>IF (7 or above):</b> 11.35</p><p><b>Relevance Score:</b> 0.14</p></div><div class="everything-else-tail"><p><b>Abstract:</b> It is well acknowledged that immune system is deeply involved in cancer initiation and progression, and can exert both pro-tumorigenic and anti-tumorigenic effects, depending on specific microenvironment.  With the better understanding of cancer-associated immune cells, especially T cells, immunothe ....</p></div></td></div></tr><tr><div class="row"><td></td><div class="col"><td><div class="everything-else-head"><h4 class="title">Title: Single-cell transcriptome analysis reveals TOX as a promoting factor for T cell exhaustion and a predictor for anti-PD-1 responses in human cancer.</h4><p><a href="https://ncbi.nlm.nih.gov/pubmed/32111241">Link</a></p><p><b>Date:</b> 02/29/2020</p><p><b>Authors:</b> Kyungsoo Kim ...  Insuk Lee</p><p><b>Journal:</b> Genome Med</p><p><b>IF (7 or above):</b> 10.47</p><p><b>Relevance Score:</b> 0.14</p></div><div class="everything-else-tail"><p><b>Abstract:</b> BACKGROUND: T cells exhibit heterogeneous functional states in the tumor microenvironment.  Immune checkpoint inhibitors (ICIs) can reinvigorate only the stem cell-like progenitor exhausted T cells, which suggests that inhibiting the exhaustion progress will improve the efficacy of immunotherapy.</p></div></td></div></tr></table></div><hr></div></body></html>